Johnson and Johnson to pay $2 billion fine of drug marketing
(KPLR) – Johnson and Johnson will pay more than $2 billion dollars to settle charges that the company marketed drugs for unapproved uses.
They were also charged with paying kickbacks to doctors and nursing homes.
The U.S. Attorney General announced the penalties today, which involves the schizophrenia drugs risperdal and invega, and the heart failure drug natrecor.
Risperdal was approved to treat schizophrenia, but also marketed to doctors to treat elderly patients with dementia.
The company also knew patients were at increased risk for developing diabetes, but did not publicly acknowledge the risk.
- McDonald’s accidentally hands out money at drive-thru
- Gay waitress loses job, accused of forging offensive note on tip
- Best Flight Ever: Airline makes passengers’ Christmas wishes come true
- Watch this: Smoking medical marijuana transforms woman with Cerebral Palsy
- Police: Newlyweds lure man through Craigslist for thrill killing